{"slug":"biliary","tag":"biliary","variants":["biliary"],"description":"No description yet","count":8,"kinds":{"person":7,"cancer":1},"related":[{"slug":"trialist","tag":"trialist","shared":6},{"slug":"hcc","tag":"hcc","shared":3},{"slug":"chemotherapy","tag":"chemotherapy","shared":1},{"slug":"fgfr2","tag":"fgfr2","shared":1},{"slug":"gastrointestinal","tag":"gastrointestinal","shared":1},{"slug":"immunotherapy","tag":"immunotherapy","shared":1},{"slug":"rare","tag":"rare","shared":1},{"slug":"surgery","tag":"surgery","shared":1},{"slug":"targeted-therapy","tag":"targeted-therapy","shared":1}],"records":[{"id":"ghassan-abou-alfa","kind":"person","name":"Ghassan K. Abou-Alfa","route":"/people/ghassan-abou-alfa/","tldr":"Led HIMALAYA and ClarIDHy, which gave liver cancer a dual-immunotherapy option and biliary cancer its first targeted drug."},{"id":"juan-valle","kind":"person","name":"Juan W. Valle","route":"/people/juan-valle/","tldr":"Led ABC-02, which made gemcitabine plus cisplatin the global standard for biliary cancer, and co-led TOPAZ-1."},{"id":"lipika-goyal","kind":"person","name":"Lipika Goyal","route":"/people/lipika-goyal/","tldr":"Led the futibatinib trial and defined how FGFR2-driven bile duct cancers become resistant to targeted drugs."},{"id":"john-primrose","kind":"person","name":"John N. Primrose","route":"/people/john-primrose/","tldr":"British surgeon who led BILCAP, the trial that made six months of capecitabine the standard after surgery for bile duct and gallbladder cancer."},{"id":"robin-kate-kelley","kind":"person","name":"Robin Kate Kelley","route":"/people/robin-kate-kelley/","tldr":"San Francisco oncologist who was lead author of KEYNOTE-966, which showed that adding pembrolizumab to gemcitabine and cisplatin helps people with advanced bile duct cancer live longer."},{"id":"angela-lamarca","kind":"person","name":"Angela Lamarca","route":"/people/angela-lamarca/","tldr":"Oncologist who was lead author of ABC-06, the first randomised trial to show that second-line chemotherapy helps people with advanced bile duct cancer."},{"id":"andrew-zhu","kind":"person","name":"Andrew X. Zhu","route":"/people/andrew-zhu/","tldr":"Oncologist who led REACH-2, the first positive biomarker-selected trial in liver cancer, which established ramucirumab for patients with a high alpha-fetoprotein level."},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","tldr":"Gallbladder cancer is a biliary tract cancer of the bile-storing sac under the liver, most often found by chance when the gallbladder is removed for stones. Caught early, a second operation to clear the liver bed and nodes can cure it; for advanced disease, chemotherapy now comes with an immunotherapy partner, and HER2-directed antibodies help the subset whose tumours over-express HER2."}]}